Skip to main content

Advertisement

SpringerLink
Log in

Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis

  • REVIEW
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Ramucirumab is a monoclonal antibody against Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) approved for the treatment of several solid tumours. As shown in recent trials results, new-onset hypertension is one of the most frequent adverse events associated with ramucirumab therapy. Recent studies looked at the quantification of the risk of hypertension in patients receiving other anti-angiogenesis medications. We conducted a meta-analysis of randomized clinical trials with the aim to investigate the incidence and quantify the risk of new-onset hypertension of any grade in patients treated with ramucirumab. Our research suggests that hypertension is frequently associated with ramucirumab therapy, with an OR of 3.60 for any grade of hypertension and an even stronger correlation with grade 3–4 hypertension (OR 4.16). These data suggest that a strict monitoring, as well as early intervention protocols, are recommended in patients receiving the drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676

    Article  CAS  PubMed  Google Scholar 

  2. Spratlin JL, Cohen RB, Eadens M et al (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780–787

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911):31–39

    Article  CAS  PubMed  Google Scholar 

  4. Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224–1235

    Article  CAS  PubMed  Google Scholar 

  5. Roviello G, Polom K, Petrioli R et al (2016) Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumour Biol 37(1):127–40

  6. Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665–673

    Article  CAS  PubMed  Google Scholar 

  7. Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 16(5):499–508

    Article  CAS  PubMed  Google Scholar 

  8. Zhu AX, Park JO, Ryoo B et al (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 16(7):859–870

    Article  CAS  PubMed  Google Scholar 

  9. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA Group PRISMA Group preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS Med 6:e1000097

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12

    Article  CAS  PubMed  Google Scholar 

  11. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  CAS  PubMed  Google Scholar 

  12. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129

    Article  Google Scholar 

  13. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    Article  PubMed  PubMed Central  Google Scholar 

  14. Yoon HH, Bendell JC, Braiteh FS et al (2016) Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter phase II trial. Ann Oncol 27(12):2196–2203

  15. Moore M, Gill S, Asmis T et al (2016) Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Ann Oncol 27(12):2216–2224

  16. Yoh K, Hosomi Y, Kasahara K et al (2016) A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer 99:186–193

    Article  PubMed  Google Scholar 

  17. Fraeman KH, Nordstrom BL, Luo W et al (2013) Incidence of new-onset hypertension in cancer patients: a retrospective cohort study. Int J Hyperts 2013 :10Article ID 379252

    Google Scholar 

  18. Chen J, Lu Y, Zheng Y (2015) Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 9:4751–4760

    PubMed  PubMed Central  Google Scholar 

  19. Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F, Cao J, Xu LM (2015) Value of bevacizumab in treatment of colorectal cancer: a meta-analysis. World J Gastroenterol 21(16):5072–5080

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Dionísio de Sousa IJ, Ferreira J, Rodrigues J et al (2016) Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer. ESMO Open 1(3):e000045

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Medical Oncology Unit, San Donato Hospital, Via Nenni 20, 52100, Arezzo, Italy

    Giandomenico Roviello

  2. Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy

    Giandomenico Roviello & Daniele Generali

  3. Department of Medical, Surgical and Neurological Sciences, Unit of Raiotherapy, University Hospital Siena, Siena, Italy

    Chiara Pacifico

  4. Radiation Oncology Department, Peter MacCallum Cancer Centre, Moorabbin Campus, East Bentleigh Victoria, 3165, Australia

    Paola Corona

  5. Unit of Molecular therapy and Pharmacogenomic, ASST Cremona, Viale Concordia 1, 26100, Cremona, Italy

    Daniele Generali

Authors
  1. Giandomenico Roviello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiara Pacifico
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paola Corona
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniele Generali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giandomenico Roviello.

Ethics declarations

Conflict of interest

Roviello G declares that he has no conflict of interest. Pacifico C declares that he has no conflict of interest. Corona P declares that he has no conflict of interest. Generali D declares that he has no conflict of interest.

Funding

The work was supported by the Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

For this type of study, formal consent is not required.

Electronic supplementary material

ESM 1

(DOCX 57 kb)

ESM 2

(DOCX 81 kb)

ESM 3

(DOCX 80 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roviello, G., Pacifico, C., Corona, P. et al. Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis. Invest New Drugs 35, 518–523 (2017). https://doi.org/10.1007/s10637-017-0452-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-017-0452-1

Keywords

Search

Navigation